Hepatic impairment doesn't effect the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after an individual 5 mg dose was evaluated in clients with diverse degrees of hepatic impairment (gentle, average, critical) compared with subjects with normal hepatic function [see Use In Unique Populations].The commencing dose of 2.5 millig